C hromosomal translocation t(8;21)(q22;q22) which leads to the generation of oncogenic RUNX1-RUNX1T1 (AML1-ETO) fusion is observed in approximately 10% of acute myelogenous leukemia (AML). To identify somatic mutations that co-operate with t(8;21)-driven leukemia, we performed whole and targeted exome sequencing of an Asian cohort at diagnosis and relapse. We identified high frequency of truncating alterations in ASXL2 along with recurrent mutations of KIT, TET2, MGA, FLT3, and DHX15 in this subtype of AML. To investigate in depth the role of ASXL2 in normal hematopoiesis, we utilized a mouse model of ASXL2 deficiency. Loss of ASXL2 caused progressive hematopoietic defects characterized by myeloid hyperplasia, splenomegaly, extramedullary hematopoiesis, and poor reconstitution ability in transplantation models. Parallel analyses of young and >1-year old Asxl2-deficient mice revealed age-dependent perturbations affecting, not only myeloid and erythroid differentiation, but also maturation of lymphoid cells. Overall, these findings establish a critical role for ASXL2 in maintaining steady state hematopoiesis, and provide insights into how its loss primes the expansion of myeloid cells. Vikas Madan, approach has identified additional mutagenic events involving ASXL2, ASXL1 and DHX15 genes in t(8;21) AML. [5] [6] [7] [8] [9] [10] Several secondary genetic events that co-operate with RUNX1-RUNX1T1 fusion in inducing leukemia have been demonstrated using mouse models. [2] [3] [4] 11 ASXL1, ASXL2 and ASXL3 are human homologs of Drosophila Asx (Additional sex combs) and function as epigenetic regulators through recruitment of Polycomb group repressor complexes (PRC) and Trithorax group activator complexes. 12, 13 ASXL proteins can interact with BAP1, NCOA1, EZH2, WTIP and nuclear receptors, which suggests diverse functions of ASXL family members in epigenetic and transcriptional regulation. 12, 13 Somatic mutations of ASXL1 occur in a range of hematologic disorders, [14] [15] [16] [17] [18] [19] [20] and its deletion in mouse hematopoietic cells results in multilineage cytopenias and dysplasia, which are associated with global reduction of H3K27 trimethylation. 21 In contrast, somatic mutations of ASXL2 are observed exclusively in t(8;21) AML, 5, 8 while mutations of ASXL3 are not reported in hematologic malignancies. 13 Silencing of ASXL2 is partially embryonic lethal depending on the genetic background, and leads to congenital heart defects. Surviving homozygous Asxl2 mutant mice are smaller than wild-type littermates, demonstrate skeletal homeotic transformations consistent with disruption of Polycomb/Trithorax complex functions, develop cardiac dysfunction, and exhibit decreased bone mineral density. [22] [23] [24] [25] [26] More recently, its role in normal hematopoietic development and leukemic development has been investigated. 27, 28 In the present study, we used exome sequencing to identify somatic mutations co-operating with RUNX1-RUNX1T1 rearrangement in AML. Frequent truncating mutations of ASXL2 were identified in our t(8;21) AML cohort. Using an Asxl2-deficient mouse model, we aimed to clarify the function of ASXL2 in hematopoiesis. We demonstrate that ASXL2 is crucial to maintain hematopoietic stem cell (HSC) number and function. Loss of ASXL2 leads to myeloproliferation and extramedullary hematopoiesis, as well as to progressive defects in multilineage differentiation. These results establish ASXL2 as a key component of the epigenetic machinery involved in maintaining hematopoietic development.
ASXL2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion

Methods
Acute myelogenous leukemia samples t(8;21) AML was diagnosed by karyotypic analysis and/or reverse transcriptase PCR assay for the detection of fusion transcript of RUNX1-RUNX1T1. Samples were collected with informed consent at diagnosis, during complete remission, and at time of frank relapse in accordance with the Declaration of Helsinki. Bone marrow (BM) mononuclear cells were obtained by Ficoll-Hypaque density gradient centrifugation (1.077 g/mL; Amersham Pharmacia, Sweden). The study was approved by the institutional review boards of the respective institutes.
Exome sequencing and somatic variant discovery
DNA was sheared using a Covaris instrument and assessed on a 2100 Bioanalyzer. Library preparation and exome sequencing were performed as described previously. 29 For whole exome sequencing, DNA were captured using SureSelect Human All Exon 50Mb kit (Agilent), according to the manufacturer's instructions. For targeted capture library, Agilent's SureSelect XT2 Target Enrichment System for Illumina Multiplexed Sequencing was used. RNA baits were designed to capture exons of 530 genes (Online Supplementary Table S1) and libraries were sequenced on  HiSeq 2000 (Illumina). 100 bp paired-end reads were aligned to human reference genome (reference build: hg19) using bwa-mem aligner with default parameters. PCR duplicate reads were marked with samblaster. 30 Resulting BAM files were further processed according to GTAK best practices including INDEL re-alignment and base quality recalibration (https://software.broadinstitute.org/gatk/best-practices/bp_3step.php?case=GermShortWGS). Somatic variants were detected using Varscan2 somatic command. 31 Raw variants were processed with processSomatic command with the P-value set to 0.05 to obtain high confident variants. Variants were further processed using fpFilter per script to remove potential false positives (https://github.com/ckandoth/variant-filter). Resulting variants were annotated using Variant Effect Predictor and filtered against germline variants in both dbSNP and ExAC, while keeping deleterious and clinically significant variants. 32 For samples without germline controls, variants were called using MuTect using a panel of normal derived from in-house cohort of AML remission samples, as described previously. 29, 33 Oncoplots were drawn using maftools Bioconductor package. 34 All the somatic mutations for whole exome sequencing and about 90% mutations reported for targeted exome sequencing were validated using PCR amplification and Sanger sequencing.
Mice
Mice with Asxl2 gene-trap allele [referred to as knockout (KO) allele in this study] have been described previously.
24 Asxl2 heterozygous KO mice were maintained on C57BL/6J (B6) and 129Sv (129) 
Flow cytometry
Cells were incubated with fluorochrome-conjugated antibodies for 30 min on ice, washed and resuspended in SYTOX Blue Dead Cell Stain (ThermoFisher Scientific) before acquisition on FACS LSR II flow cytometer (BD Biosciences). Sorting of cells was performed on FACSAria cell sorter (BD Biosciences) and data were analyzed using FACSDIVA software (BD Biosciences). See Online Supplementary Table S2 for the list of antibodies used for flow cytometric staining.
Statistical analysis
All statistical analyses were performed using GraphPad Prism 7 software.
Accession numbers
The accession numbers for the sequencing data reported in this study are SRP122878 (exome sequencing) and GSE106798 (RNA sequencing).
Results
Mutational profile of RUNX1-RUNX1T1 AML
We performed whole-exome sequencing of 10 paired samples of newly-diagnosed and relapsed AML with RUNX1-RUNX1T1 rearrangement from an Asian cohort, Progressive hematopoietic defects in ASXL2 KO mice haematologica | 2018; 103 (12) along with matched germline (complete remission) DNA (Online Supplementary Table S3 ). We achieved a mean depth of 100x (range 64-271x); an average 68% of nucleotides were covered by at least 20 reads (Online Supplementary Figure S1 ). We identified 55 somatic mutations (in 52 genes) in newly-diagnosed cases and 76 mutations (in 69 genes) at relapse, which included recurrent mutations in KIT, TET2, DHX15 and MGA (Online Supplementary Table S4 ). We assessed the stability of mutations in diagnosis and relapse samples analyzed using whole exome sequencing. Overall, the disease evolution followed the pattern reported previously for AML, 35 as the founding clone or a subclone at diagnosis survived the therapy, gained additional mutations, and expanded at relapse (Online Supplementary Figure S2) . Interestingly, all four mutations of TET2 (in 3 cases) were acquired at relapse (Online Supplementary Table S4 ).
Further to uncovering the repertoire of co-operating mutations in t(8;21) AML, we analyzed mutational status of 530 genes (Online Supplementary Table S1 ) in 76 newlydiagnosed and 19 relapse t(8;21) AML cases using targeted-exome sequencing (Online Supplementary Table S3 ). In this cohort, the mean sequencing coverage across targeted bases was 96x (range 76-319x), with 70% of bases covered greater than 20x (Online Supplementary Figure S1 ).
Overall, we observed that the mutations of KIT were most frequent at both diagnosis and relapse in our cohort, along with recurring alterations in ASXL2, MGA, DHX15, TET2 and FLT3 genes ( Table S5) .
ASXL2 was the second most frequently mutated gene, and interestingly, all alterations were truncating mutations located in exons 11 and 12 ( Figure 1 and Online Supplementary Figure S3 ). Unlike alterations of ASXL1, which are recurrent in several hematologic diseases, recent reports 5, 8, 9 have highlighted the incidence of ASXL2 mutations specifically in the t(8;21) subtype of AML. In this study, we aimed to investigate the consequences of deficiency of ASXL2 on hematopoietic development using a mouse model.
Impaired hematopoiesis in Asxl2-deficient mice
Our RT-PCR analysis showed that Asxl2 is expressed in a broad range of murine hematopoietic cell types (Online Supplementary Figure S4A) . To investigate the physiological role of ASXL2 in steady-state hematopoiesis, we used genetrap mice (referred to as Asxl2 KO mice) described previous-V. Madan et al. 1982 haematologica | 2018; 103(12) ly. 24 As reported, 24 Asxl2 KO mice had a significantly shorter life span compared with the WT mice (Online Supplementary Figure S4B ). We observed a significant reduction in Asxl2 transcript and protein levels in the BM, spleen and thymus of Asxl2 KO mice compared to WT mice (Online Supplementary Figure S5A-F) , whereas the expression of Asxl1 was not affected (Online Supplementary Figure S5G 
-I).
We cultured the BM cells from WT and KO mice for two weeks in myeloid differentiation-promoting conditions and observed an increase in the proportion of CD11b + cells with a concomitant decrease in Lin -Kit + cells in the cultures from Asxl2-deficient BM, suggesting altered myeloid differentiation (Online Supplementary Figure S6A and B) . Moreover, in re-plating assays, we observed a sustained ability of Asxl2 KO BM cells to generate myeloid colonies compared with WT cells (Online Supplementary Figure S6C) .
To gain initial insights into the effect of ASXL2 deficiency on hematopoiesis in vivo, we periodically analyzed the peripheral blood (PB) from Asxl2 KO and WT mice beginning at eight weeks of age. We observed an age-dependent increase in white leukocyte count in the PB of Asxl2-deficient mice, while the numbers were unchanged in the WT mice (Figure 2A ). This was associated with reduced red blood cell (RBC) counts and hemoglobin in peripheral blood of Asxl2 KO mice with increasing age (Online Supplementary Figure S7 ). This observation suggested progressive defects in the hematopoietic compartment in Asxl2 KO mice, and therefore we investigated systematically hematopoietic development in >1-year old mice. Flow cytometric analysis of blood leukocytes from these mice showed a higher proportion of myeloid (CD11b Figure S9E) . We also detected markedly increased frequency of stem/progenitor cells in the peripheral blood of old KO mice ( Figure 2G and Online Supplementary Figure S9F) .
Parallel analyses of spleens from young KO mice (8-14 weeks old) revealed modestly increased spleen size with a trend towards elevated proportion and number of LSK cells (Online Supplementary Figure S10A-C) . A propensity for increased frequencies of myeloid cells (CD11b + ) and erythroid progenitors was also noted in the spleens of young KO mice (Online Supplementary Figure S10D and E) . This indicates an onset of extramedullary hematopoiesis in young mice, which manifests by marked myeloid and erythroid cell expansion as the mice grow older.
ASXL2 deficiency results in defective differentiation and function of hematopoietic stem cells
ASXL2 deficiency resulted in paler bones and decreased marrow cellularity in old mice ( Figure 3A and B) . Notably, BM of old Asxl2 KO mice had higher frequency and absolute number of LSK cells compared with the WT mice ( Figure 3C and Online Supplementary Figure S11A Figure S11C) , albeit an overall increase in the absolute number of these subpopulations occurred in the old KO mice (Online Supplementary Figure S11D and E). We also observed reduced BM cellularity in young KO mice; and although the proportion of LSK cells was not significantly altered, the frequency and absolute numbers of LT-HSCs were significantly higher, suggesting early defects in maintaining HSC frequency (Online Supplementary Figure S11F-J) . In vivo BrdU incorporation assay uncovered a significantly higher frequency of BrdU + LSK cells in the BM of Asxl2 KO mice, indicating increased cycling of stem/progenitor cells lacking ASXL2 ( Figure  3D) Figure S12A and B) . Furthermore, a marked reduction in the frequencies of erythroid precursors was noted in the old KO mice ( Figure 3F and Online Supplementary Figure S12C) , indicating impaired erythropoiesis. Reduction in erythroid precursors as well as CMP and GMP populations was also apparent in the BM of the young KO mice, signifying an early inception of defects in erythroid and myeloid differentiation because of ASXL2 deficiency (Online Supplementary Figure S12D-F) .
Further, multi-lineage reconstitution ability of Asxl2-deficient HSCs was assessed in a competitive repop- Figure 3G and H). The reconstitution of granulocytes was also impaired in mice transplanted with Asxl2-deficient LSK cells ( Figure 3I ), while the proportion of donor-derived monocytes was similar to the recipients transplanted with WT cells ( Figure 3J ). These repopulation assays demonstrated that ASXL2 is essential for differentiation into multiple hematopoietic lineages including the lymphoid lineage, prompting us to investigate the development of lymphoid lineage in the Asxl2 KO mice.
Impaired thymopoiesis in mice lacking ASXL2
A marked reduction of thymus size and cellularity was a consistent feature in >1-year old Asxl2 KO mice compared with the WT mice ( Figure 4A Figure 4D and Online Supplementary Figure S13B) . Further characterization showed that the vast majority of cells in the DN gate were CD19 + (which contributed to 40% of total thymus-residing hematopoietic cells), and the frequency and number of CD11b + myeloid cells were also noticeably increased in the thymus of KO mice compared with the WT mice ( Figure 4F and G and Online Supplementary Figure S13C-F) .
Young Asxl2 KO mice exhibited decreased thymus cellularity, but displayed less pronounced effect on major thymic compartments compared with the >1-year old mice (Online Supplementary Figure S13G-I) . These findings illustrate that ASXL2 is essential for maintaining normal thymopoiesis in mice and its deficiency leads to progressive impairment in thymocyte maturation, which is manifested by a partial block from the DN to the DP stage, and an accumulation of myeloid and B cells in the thymus of the old mice.
Defects in B-cell development in Asxl2 knockout mice
We also examined the consequences of ASXL2 deficiency on B-cell development in the BM by examining the expression of several surface antigens, which define the advancing stages of B-cell maturation. While the young Asxl2 KO mice showed largely conserved subsets during B-cell lymphopoiesis, a notable decrease in the proportion of mature B cells (CD43 Figure S14 ).
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haematologica | 2018; 103(12) Figure 5A and B) , demonstrating a partial arrest of B-cell maturation.
Cell-intrinsic role of ASXL2 in hematopoiesis
To test the cell-autonomous function of ASXL2 in hematopoietic development, we transplanted lethally irradiated mice with either WT or Asxl2 KO BM cells and analyzed the hematopoietic compartment one year later. We observed that the recipient mice transplanted with Asxl2 KO BM cells tended to have higher WBC counts in peripheral blood ( Figure 6A ), similar to the age-dependent increase in WBC observed in KO mice (Figure 2A) . We also noted decreased thymocyte cellularity and accumulation of donor-derived DN cells in the thymi of mice transplanted with Asxl2 KO BM compared with those transplanted with WT BM (Figure 6B and C) . Spleens of Asxl2 KO BM-recipients were enlarged and exhibited elevated proportion of myeloid cells ( Figure 6D and E) . Moreover, our analysis also indicated a higher proportion of erythroid precursors in spleens of mice reconstituted with Asxl2 KO BM cells compared with the WT cells ( Figure  6F ), similar to the phenotype observed in old Asxl2 KO mice. Overall, the recipient mice recapitulated hematopoietic features of old Asxl2 KO mice, suggesting a hematopoietic cell-intrinsic function of ASXL2.
Identification of altered gene expression in ASXL2-deficient hematopoietic stem cells
To determine the molecular basis of the defects observed in Asxl2 KO HSCs, we performed global gene expression profiling (RNA-Sequencing) of sorted LSK cells from old and young WT and Asxl2 KO mice. Comparison of transcriptomic profiles of LSK cells from old WT and Asxl2 KO identified more than 2500 genes differentially expressed (983 genes up-regulated and 1653 genes downregulated in the KO cells; FDR<0.1) (Online Supplementary  Table S6 ), including those involved in myeloid differentiation such as Csf1, Gfi1b, Gata2, Hoxa9, Hoxa5, Mpl, Cdk6, Ccr1 and Ets1 (Online Supplementary Figure S15A) . Asxl2-deficient LSK cells from old mice exhibited more pronounced changes in gene expression compared with the young mice ( Figure 7A and B and Online Supplementary Figure S15B ). However, a significant overlap of genes commonly up-regulated and down-regulated in the KO LSK cells was noted within the two age groups ( Figure 7C and Online Supplementary Table S6) . Interestingly, GSEA analysis revealed that the expression of RUNX1-RUNX1T1 targets 37 inversely correlated in the KO cells ( Figure 7D and Online Supplementary Figure S15C) . Also, genes down-regulated in immature BM progenitors upon silencing of CBFA2T3 (also called ETO2) 38 were also suppressed in the LSK cells from both old and young Asxl2 KO mice ( Figure  7E and Online Supplementary Figure S15D) . CBFA2T3 is involved in the translocation t(16;21)(q24;q22) with 
Discussion
This study, along with recent reports, 5-10 provides a comprehensive landscape of the mutational spectrum of t(8;21) AML, which is distinctive from other subtypes of AML and characterized by high frequency of alterations of KIT, ASXL2, DHX15 and MGA genes; and rare mutations of other commonly altered genes in myeloid leukemia (DNMT3A, RUNX1, IDH2, NPM1). Truncating mutations of ASXL2 occurred in 20% of newly-diagnosed t(8;21) AML cases, and were localized to exons 11 and 12, a pattern highly reminiscent of the mutational profile for ASXL1 in hematologic malignancies. 41, 42 However, unlike ASXL1, which is altered in a diverse range of hematologic diseases, mutations of ASXL2 are specific to the t(8;21) AML subtype. We also noted that the mutational frequency of RAS pathway genes (NRAS and KRAS) and ZBTB7A in our Asian cohort of t(8;21) AML were notably lower V. Madan et al. 1988 haematologica | 2018; 103(12) 
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than previous reports from Western populations. 5, [7] [8] [9] 40, 43 We obtained a mutational rate of 6% for NRAS and 2% for KRAS compared to 13-26% for NRAS and 4-7% for KRAS observed in previous studies. 5, [7] [8] [9] 43 Similarly, ZBTB7A mutations that are frequent in Caucasian t(8;21) AML (9-23%) 9, 40, 43 were observed in only 3% of our Asian patient cohort. Although this might reflect a true difference between genetic backgrounds, this requires further confirmation in independent t(8;21) AML cohorts from different genetic backgrounds.
In this study, we focused on functional characterization of Asxl2 in hematopoietic differentiation using a mouse model of Asxl2 deficiency. Mice used in this study were C57BL/6 x 129Sv F1 as the animals in either C57BL/6 or 129Sv background die perinatally, 23 which precludes investigation of Asxl2 knockout on an inbred genetic background. Moreover, this mouse model exhibits constitutive loss of Asxl2, which is distinct from the truncating somatic mutations of ASXL2 observed in t(8;21) AML that may possibly generate a C-terminal truncated protein. Despite these limitations, our study strengthens the findings concerning the key role of ASXL2 in hematopoiesis reported in two recent studies. 27, 28 Furthermore, our study reports several additional features of Asxl2 deficient mice, which had not been described previously. While the significance of ASXL2 in maintaining normal hematopoiesis is evidenced from these studies, we performed a parallel indepth analysis in young (8-14 weeks old) versus old (>1-year old) mice, which helped establish the progressive phenotype associated with Asxl2 deficiency, including uncovering the crucial function of ASXL2 in development of the lymphoid lineage. Age-dependent defects in hematopoiesis in the knockout mice were characterized by an increased proportion of LSK cells and reduced frequencies of CMP and GMP cells in the BM of >1-year old KO mice. Asxl2-deficient mice also exhibited a progressive myeloproliferative phenotype, accompanied by increased peripheral WBC counts, splenomegaly and extramedullary hematopoiesis, indicating perturbed hematopoiesis. In addition, erythroid maturation was impaired in the old mice lacking ASXL2, signifying agedependent defects in erythroid development. Both previous studies showed that ASXL2 deficiency led to poor reconstitution ability of HSCs in transplantation models, consistent with our findings. We observed that Asxl2-deficient LSK cells exhibited poor reconstitution ability of the lymphoid lineage and flow cytometric analyses of >1-year old mice demonstrated defects in both T-cell maturation in the thymus and B-cell development in the BM of the old KO mice. Apart from the intrinsic effect of ASXL2 on lymphoid differentiation, chronic overproduction of myeloid cells and accompanying inflammatory signals in the mice lacking ASXL2 may also negatively affect the lymphoid output. These findings establish ASXL2 as an essential component of hematopoietic development in mice.
Gene expression analysis of sorted LSK cells from WT and Asxl2 KO BM identified several key regulators of hematopoiesis as downstream targets of ASXL2 in HSCs. Prominently, GSEA analysis revealed that the expression of genes regulated by RUNX1-RUNX1T1 correlated with the expression of ASXL2, indicating ASXL2 is possibly required for transcriptional activity of RUNX1-RUNX1T1. An identical finding was described recently for Asxl2-deficient LSK cells in an independent mouse model. Here the authors also detected binding of ASXL2 to the genomic loci occupied by RUNX1 and RUNX1-RUNX1T1, although no direct interaction between ASXL2 and either RUNX1 or RUNX1-RUNX1T1 was observed. 27 Further studies are needed to investigate whether ASXL2 acts as a likely co-regulator of RUNX1-RUNX1T1 during leukemogenesis. GSEA also indicated a correlation between Asxl2 deficiency and the expression levels of reported targets of BMI1 (a PRC1 member) 44 and SUZ12 (a PRC2 member) 45 (Online Supplementary Figure S15E and F), consistent with a role for ASXL2 in transcriptional regulation mediated through the PRC complexes.
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In summary, the current study identified frequent ASXL2 mutations in t(8;21) AML and characterized its role in hematopoietic development in mice. This work demonstrates that ASXL2 plays a critical role in multi-lineage differentiation and highlights how its loss leads to progressive hematopoietic defects and promotes myeloid expansion, thereby advancing our understanding of epigenetic machinery that regulates hematopoiesis.
